FIELD: medicine.
SUBSTANCE: described are novel versions of erythropetine (EPO), representing deleted forms of hormone, which possess cytoprotective, in particular, neuroprotective, function, without, in fact, demonstrating hemopeotic activity, as well as their obtaining by method of recombinant DNAs and means requited for its realisation (vector constructions and host-cells).
EFFECT: claimed is application of novel EPO versions with cytoprotective action as active agent in manufacturing medicines for treatment or prevention of state, associated with tissue damage induced by cell death.
22 cl, 30 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED HUMAN ERYTHROPOIETIN | 2019 |
|
RU2827791C2 |
| POLYPEPTIDE-LIGAND FLT3 (VARIANTS), POLYNUCLEOTIDE (VARIANTS), EXPRESSING VECTOR (VARIANTS), STRAIN OF CELL CHO (VARIANTS), METHOD FOR PRODUCING POLYPEPTIDE-LIGAND FLT3 (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) | 1994 |
|
RU2220979C2 |
| FUSED PROTEIN WITH ENHANCED ERYTHROPOIETIN ACTIVITY, NUCLEIC ACID ENCODING FUSED PROTEIN AND METHOD FOR PREPARING FUSED PROTEIN | 2002 |
|
RU2232192C2 |
| IMPROVED NOGO-A-BINDING MOLECULES AND PHARMACEUTICAL APPLICATION THEREOF | 2008 |
|
RU2513697C2 |
| INTERFERON-LIKE PROTEIN ZCYTO21 | 2001 |
|
RU2292394C2 |
| RECOMBINANT MOLECULES OF LUBRICIN AND THEIR USE | 2004 |
|
RU2376313C2 |
| NEW LIGAND OF CYTOKINE RECEPTOR ZCYTOR17 | 2003 |
|
RU2490276C2 |
| NEW ISOFORMS OF VASCULAR ENDOTHELIAL CELL GROWTH INHIBITOR | 2002 |
|
RU2316591C2 |
| AMPLIFIER T-CELL RESPONSE TO VACCINE | 2018 |
|
RU2794196C2 |
| EUKARYOTIC EXPRESSION VECTORS CONTAINING REGULATORY ELEMENTS OF GLOBIN GENE CLUSTERS | 2016 |
|
RU2716974C2 |
